

Anelixis Therapeutics, LLC Patent Overview (November, 2017)

For more information, visit www.anelixistherapeutics.com



Methods for the treatment of Neurodegenerative Disease					
Country	Application No.	Filing date	Publication or Patent Number	Publication or Issue Date	Status
US provisional	61/120,121	12/5/2008	N/A	N/A	Expired
PCT	PCT/US2009/066715	12/4/2009	WO2010/065819	6/10/2012	Nationalized
US	13/858667	8/18/2011	8,435,514	5/7/2013	Issued
US (Divisional)	13/858,667	4/8/2013	9,044,459	6/2/2015	Issued
Hong Kong	11112885.0	11/28/2011	1158660	7/20/2012	Pending
Japan	2011-095123	5/7/2015	6027646	10/21/2016	Issued
Europe	EP 09768576.2	12/4/2009	EP2367849	9/28/2011	Pending

Anti-CD40L Therapeutic Antibodies					
Country	Application No.	Filing date	Publication or Patent Number	Publication or Issue Date	Status
US provisional	62/111,261	2/3/2015	N/A	N/A	Expired
PCT	PCT/US2016/016165	2/2/2016	WO 2016/126702	8/11/2016	Pending

*The term of 9,044,459 is extended by 116 days for patent term adjustment.

We are aware of no constraints, intellectual property or otherwise, that would impede or block the use of any proposed assay or model or would block or impede commercial development of AT-1501 for the treatment of ALS. We have worked with outside counsel to do preliminary patent clearance searches and have not identified any patents that will block development or marketing of AT-1501 in the U.S.